Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9C091
UPID:
GRB1L_HUMAN
Alternative names:
Growth regulation by estrogen in breast cancer 1-like protein
Alternative UPACC:
Q9C091; A4QN17; Q9H8F1
Background:
The GREB1-like protein, also known as Growth regulation by estrogen in breast cancer 1-like protein, plays a pivotal role in the development of the metanephros and genitalia. Its involvement in early kidney and reproductive system development underscores its biological significance.
Therapeutic significance:
Linked to Renal hypodysplasia/aplasia 3 and Deafness, autosomal dominant, 80, the GREB1-like protein's genetic variants highlight its critical role in kidney development and hearing. Understanding its function could pave the way for innovative treatments for these conditions.